Advertisement

Related Videos

Opening Session Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Dec
03
Today In Oncology
Addition of Neoadjuvant LuPSMA PNT2002 to SBRT in Oligorecurrent Prostate Cancer
Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
Image-Only AI Model Outperforms Breast Density for 5-Year Breast Cancer Risk Stratification
Tisagenlecleucel in Relapsed or Refractory Large B-Cell Lymphoma
Retrospective Review Shows Persistent Breast Cancer Burden in Younger Women
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo